Skip to Main Content

Pfizer has a lot going on these days: It’s developing Omicron booster shots, plans to test its Covid pill, Paxlovid, in children younger than 12, and it’s on the hunt for deals.

What do all of those things have to do with each other? They will all fall under the remit, entirely or in part, of the company’s new chief development officer, William Pao, who Pfizer announced Tuesday it had hired from Roche, where he was head of early research.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment